Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ: NTLA )

9.230 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential
Biotech stocks, namely those involved with gene editing, have been explosive and could see higher highs with strong catalysts. 
Via InvestorPlace
Analysts Say Intellia Therapeutics Stock Could Rise 157% This Year, but Will It Happen?
Good news may be on the way, but it will be a while before it arrives. 
Via The Motley Fool
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
From ReCode Therapeutics
Via Business Wire
Analysts see over 50% gains in these 2 mid-cap biotech stocks
The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
Is It Too Late to Buy Intellia Therapeutics Stock?
2024 could be an important year for the biotech. 
Via The Motley Fool
3 Gene Editing Stocks With Unprecedented Surge Potential
While CRISPR will certainly be exciting to watch, here are some other gene-editing stocks with unprecedented surge potential. 
Via InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy in February 2024
With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider. 
Via InvestorPlace
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The widely followed growth investor keeps making moves. 
Via The Motley Fool
Not Shy Of Buying The Dip, Cathie Wood's Ark Mops Up Over $11M Worth Of Shares In Tesla — Sells Nvidia Stock
Via Benzinga
A Bull Market Is Here: 2 Top Growth Stocks to Buy Hand Over Fist
These biotech innovators have what it takes to soar. 
Via The Motley Fool
Cathie Wood's Ark Invest Snatches Up $4.7M More In Tesla Shares, Invests Equally In This Rocket Company
Via Benzinga
3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential
Some of the top gene-editing stocks have had immense surge potential. Look at CRISPR Therapeutics, for example. 
Via InvestorPlace
History Says the S&P 500 May Climb in the Triple Digits During This Bull Market. 3 Top Growth Stocks to Buy Before it Does.
Bull markets generally favor growth stocks, so now is a great time to buy quality growth players. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
2 Growth Stocks That Could Rocket 144% and 202% Higher This Year, According to Wall Street
Expectations for these stocks are sky-high, but so are the risks. 
Via The Motley Fool
3 Biotech Stocks to Turn $10,000 Into $1 Million: January 2024
Biotech stocks are some of the most exciting opportunities on the market. Find the right ones with catalysts, and you could make a fortune. 
Via InvestorPlace
Better Growth Stock: Intellia Therapeutics vs. CRISPR Therapeutics
Both companies are going to continue doing high-impact science in 2024. 
Via The Motley Fool
The Top Healthcare Stocks to Buy With $100
These companies are shaping the healthcare of tomorrow. 
Via The Motley Fool
Voyager Therapeutics stock pops 30% on deal with Novartis
Voyager Therapeutics Inc. (NASDAQ: VYGR) is a biotech in the medical sector that specializes in gene therapy for neurological diseases. Its shares took 
Via MarketBeat
Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics
These two are at very different stages of the clinical trials process. 
Via The Motley Fool
4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024
Even if Wall Street is wrong about these stocks in the new year, Cathie Wood could still be right about them over the long run. 
Via The Motley Fool
AlloVir Layoffs 2024: What to Know About the Latest ALVR Job Cuts
AlloVir layoffs are coming for 95% of the company's employees as a way to reduce costs and preserve cash after failed clinical trials. 
Via InvestorPlace
Topics Workforce
Exposures Layoff
Why Is Medical Properties Trust (MPW) Stock Down 31% Today?
Medical Properties Trust stock is falling hard on Friday as investors in MPW react to a rent repayment plan with Steward Health Care System. 
Via InvestorPlace
Intellia Therapeutics Layoffs 2024: What to Know About the Latest NTLA Job Cuts
Intellia Therapeutics layoffs are in the news on Friday as the biotech company prepares to cut its total workforce by 15% to reduce costs. 
Via InvestorPlace
Topics Workforce
Exposures Layoff
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
2 gene-editing stocks reshaping hereditary disease treatments
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal 
Via MarketBeat
2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics
Curing rare inherited illnesses could be a lucrative business model. 
Via The Motley Fool
CRISPR Therapeutics sets sights on gene-editing cures for disease
On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for 
Via MarketBeat
Exposures Product Safety
5 Beaten-Down Stocks That Could Soar in 2024
These players may offer your portfolio a lift as early as next year. But most importantly, they could excel over time. 
Via The Motley Fool
3 Gene-Editing Stocks With the Potential to Mint Millionaires
Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR. 
Via InvestorPlace
Exposures Product Safety
Could Intellia Therapeutics Become the Next CRISPR Therapeutics?
Intellia is approaching the finish line. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.